Simcere Pharmaceutical Group Crushes Earnings Estimates
Simcere Pharmaceutical Group (NYS: SCR) reported earnings on March 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Simcere Pharmaceutical Group missed estimates on revenue and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank and GAAP earnings per share contracted significantly.
Margins contracted across the board.
Simcere Pharmaceutical Group tallied revenue of $80.9 million. The four analysts polled by S&P Capital IQ hoped for net sales of $85.6 million on the same basis. GAAP reported sales were 9.1% lower than the prior-year quarter's $89.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.07. The three earnings estimates compiled by S&P Capital IQ anticipated $0.05 per share on the same basis. GAAP EPS of $0.12 for Q4 were 25% lower than the prior-year quarter's $0.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 82.3%, 180 basis points worse than the prior-year quarter. Operating margin was 0.3%, 1,040 basis points worse than the prior-year quarter. Net margin was 8.4%, 160 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $79.2 million. On the bottom line, the average EPS estimate is $0.10.
Next year's average estimate for revenue is $356.7 million. The average EPS estimate is $0.46.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 233 members out of 243 rating the stock outperform, and 10 members rating it underperform. Among 56 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 52 give Simcere Pharmaceutical Group a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Simcere Pharmaceutical Group is hold, with an average price target of $9.30.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Simcere Pharmaceutical Group the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Simcere Pharmaceutical Group to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.